Crenolanib besylate, a type I pan-FLT3 inhibitor, to demonstrate clinical activity in multiply relapsed FLT3-ITD and D835 AML.

被引：29

作者：

Cortes, Jorge E.

Kantarjian, Hagop M.

Kadia, Tapan M.

Borthakur, Gautam

Konopleva, Marina

Garcia-Manero, Guillermo

Daver, Naval Guastad

Pemmaraju, Naveen

Jabbour, Elias

Estrov, Zeev

Ramachandran, Abhijit

Paradela, Jamil

Pond, Blake

Ravandi, Farhad

Vusirikala, Madhuri

Patel, Prapti Arvind

Levis, Mark J.

Perl, Alexander E.

Andreeff, Michael

Collins, Robert

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] AROG Pharmaceut Inc, Dallas, TX USA

[3] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA

[4] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA

[5] Univ Penn, Philadelphia, PA 19104 USA

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.7008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

7008

引用

页数：4